`
`From:
`Sent:
`To:
`
`Subject:
`Attachments:
`
`PRPS SYSTEM NOTIFICATION [PRPS_Trial@uspto.gov]
`Thursday, January 21, 2016 3:50 AM
`jblake@merchantgould.com; mfedowitz@merchantgould.com; Ettinger, Heather; Robinson,
`Joseph R.; Weeks, Dustin B.; Ettinger, Heather
`Party filing notice received - IPR2015-01093
`webwbUSPTOSeal2.gif
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`PATENT TRIAL AND APPEAL BOARD
`
`Filing Courtesy Notice
`
`Please note the following filing:
`
`Case Number:
`Filer:
`Filing Date:
`
`IPR2015-01093
`NPS Pharmaceuticals, Inc. of Bedminster, NJ
`1/21/2016
`
`Document List
`Paper Name
`Transcript of Deposition
`of Anthony Palmieri III,
`Ph.D
`CV of John F. Carpenter,
`Ph.D.
`CV of Gordon Rausser,
`Ph.D.
`Jackson 2012
`Onoue 2004
`U.S. Pharmacopeia 24,
`774-77 (1999)
`
`Type
`
`Exhibit
`
`Exhibit
`
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`
`Paper / Exhibit Number
`
`2042
`
`2043
`
`2044
`2045
`2046
`2047
`
`1
`
`
`
`Joshi 2012
`Fang 2012
`Blundell 1983
`Boesch 1978
`Akers 2002
`U.S. Pharmacopeia 788
`(2011)
`Remington's
`Pharmaceutical Sciences,
`18th Ed., 1549-51 (1990)
`U.S. Patent Publication
`No. 2013/0310314
`Annex1 Summary of
`Product Characteristics
`Orange Book Listing for
`Gattex
`Eli Lilly and Co. 2012
`Al-Hussein 2013
`Izutsu 2009
`U.S. Pharmacopeia 23,
`1650-51 (1995)
`Center for Drug
`Evaluation and Research,
`Application
`Number203441Orig1s000,
`Chemistry Review(s)
`FDA - Approved Drug
`Products Zorbtive
`Shire 2015 - Shire
`Completes Acquisition of
`NPS Pharma
`Engellenner 2015 - Bass
`Goes Fishing
`Joseph Walker and Rob
`Copeland, New Hedge
`Fund Strategy WSJ
`Article_4.7.2015
`Wieczner 2015 - Why
`drug price controversey is
`great news for this hedge
`fund manager
`Buchman 2006 - Etiology
`and Initial Management of
`SBS
`Pirona 2015 - Espen
`endorsed
`recommendations
`O'Keefe 2006 - Short
`
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`2048
`2049
`2050
`2051
`2052
`2053
`
`2054
`
`2055
`
`2057
`
`2058
`2059
`2060
`2061
`2062
`
`2063
`
`2064
`
`2065
`
`2066
`
`2067
`
`2068
`
`2069
`
`2070
`
`2071
`
`2
`
`
`
`bowel syndrome and
`intestinal failure
`Buchman 1997 - The
`Clinical Management of
`Short Bowel Syndrome
`NPS 2012 - Developing
`orphan products for
`patients
`Hofstetter 2013 - Key
`Issues in Addressing The
`Clinical and Humanistic
`O'Keefe 2015 -
`Nutritional Issues in the
`SBS
`Tee 2011 - Emerging
`Treatment Options for
`SBS - Potential Role of
`Teduglutide
`Naberhuis 2015 -
`Teduglutide for Safe
`Reduction of Parenteral
`Nutrient
`Buchman 2012 -
`Teduglutide and SBS
`FDA - Approved Drug
`Products Zorbtive
`Crohn's and Colitis 2013 -
`Short Bowel Syndrome
`and Crohn's Disease
`Donohoe 2010 - Short
`Bowel Syndrome
`Zorbtive label
`Wales 2010 - Human
`growth hormone and
`glutamine
`Serono 2005 - Annual
`Report
`Part 1 Merck 2013 -
`Annual Report
`Part 2 Merck 2013 -
`Annual Report
`Keller 2004 -
`Management of the Short
`Bowel Syndrome after
`Extensive Small Bowel
`Resection
`Gattex label
`Oley Foundation 1994 -
`North American Home
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`Exhibit
`
`2072
`
`2073
`
`2074
`
`2076
`
`2077
`
`2078
`
`2079
`
`2080
`
`2081
`
`2082
`2083
`
`2084
`
`2085
`
`2086
`
`2086
`
`2087
`
`2088
`2089
`
`3
`
`
`
`Parenteral
`NPS 2011 - NPS
`Pharmaceuticals
`Announces Completion of
`Treatment Phase in
`STEPS
`Seeking Alpha - CEO
`Discusses Q1 2013
`Results
`Amiot 2013 -
`Determinants of home
`parenteral nutrition
`dependence
`McKeage 2015 -
`Teduglutide - A Guide to
`its Use in SBS
`FDA 2015 - Orange Book
`Approved Drug Products
`with Therapeutic
`Equivalence Evaluations
`Jeppesen 2014 - Spectrum
`of short bowel syndrome
`in adults - Intestinal
`insufficiency to intestinal
`failure
`AGA 2003 - Technical
`Review on Short Bowl
`Syndrome and Intestinal
`Transplantation
`Jeppesen 1999 - Quality
`of life in patients
`receiving home parenteral
`nutrition
`Jeppesen 2011 -
`Randomised placebo-
`controlled trial of
`teduglutide in
`ADA 2013 - Economic
`Cost of Diabetes in the US
`in 2012
`Rodrigues 2011 - Short
`Bowel Syndrome
`Thompson 2012 - Current
`Management of SBS
`Jeppesen 2012 -
`Teduglutide Reduces
`Need for Parenteral
`Support Among Patients
`with SBS
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`2090
`
`2091
`
`2092
`
`2093
`
`2094
`
`Exhibit
`
`2095
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`2096
`
`2097
`
`2098
`
`2099
`
`2100
`
`2101
`
`2102
`
`4
`
`
`
`Seeking Alpha - CEO
`Discusses Q2 2013
`Results
`Seeking Alpha - CEO
`Discusses Q3 2013
`Results
`Seeking Alpha - CEO
`Discusses Q4 2013
`Results
`Shire 2015 - Q3 2015
`Results
`Shire 2015 - Q3 2015
`Results
`Wolters Kluwer Price
`Data
`NPS Pharmaceuticals'
`(NPSP) CEO Francois
`Nader on Q1 2014 Results
`- Earnings Call Transcript
`Seeking Alpha - CEO
`Francois Nader on Q2
`2014 Results
`Seeking Alpha - CEO
`Francois Nader on Q3
`2014 Results
`NPS 2014 10-K
`Shire 2015 - Q1 2015
`Results
`Shire 2015 - Q2 2015
`results
`Shire 2015 - SHPG
`Flemming Ornskov on Q3
`2015 Results - Earnings
`Call Transcript
`Seeking Alpha 2013 -
`NPS Pharmaceuticals
`CEO Discusses
`Yahoo Finance - NPSP
`Historical Prices
`NPS 2013 10-K
`Moon 2014 - Biotech
`selloff could be harbinger
`of further decline Reuters
`Ashton 2014 - Biotech
`Sell Off Drags NASDAQ-
`100 Down To 2-Year
`Lows
`Nasdaq - Overview for
`NBI
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`2103
`
`2104
`
`2105
`
`2106
`
`2107
`
`2108
`
`2109
`
`2110
`
`2111
`
`2112
`2113
`
`2114
`
`2115
`
`2116
`
`2117
`2118
`
`2119
`
`2120
`
`2121
`
`5
`
`
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Yahoo Finance - NBI
`Historical Prices
`Yahoo Finance - XBI
`Historical Prices
`Shire - Patient Assistance
`Program Gattex
`SP Capital IQ 2014 - NPS
`Pharmaceuticals (NPSP) Exhibit
`Osbourne 2014 - Natpara
`sails through panel despite
`headwind
`Shire 2015 - Q1 2015 10-
`Q
`FDA 2015 - Expiration
`Dating and Stability
`Testing for Human
`Gibson 2009 -
`Pharmaceutical
`Preformulation and
`Formulation
`Cohen 2000 - Many
`medicines are potent years
`past expiration dates
`Merck 2014 - Annual
`Report
`FDA CDER - Initial
`Quality Assessment
`Herper 2012 - Inside The
`Secret World Of Drug
`Company Rebates -
`Forbes
`Shire - Sharps Disposal
`Gattex
`Shire - OnePath Support
`Program
`Klick Health - Patient
`Support Programs
`FDA 2014 - Guidance on
`Devices for Home Use
`FDA - Approved Drug
`Products Gattex
`Adempas (riociguat) -
`Aim Patient Support
`Program Overview
`Celgene - Patient Support Exhibit
`Merck 2006 - Annual
`Exhibit
`Report
`Merck 2007 - Annual
`Report
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`2122
`
`2123
`
`2124
`
`2125
`
`2126
`
`2127
`
`2128
`
`2129
`
`2130
`
`2131
`
`2132
`
`2133
`
`2134
`
`2135
`
`2136
`
`2137
`
`2138
`
`2139
`
`2140
`2141
`
`2142
`
`6
`
`
`
`Merck 2008 - Annual
`Report
`Merck 2009 - Annual
`Report
`Part 1 Merck 2010 -
`Annual Report
`Part 2 Merck 2010 -
`Annual Report
`Part 1 Merck 2011 -
`Annual Report
`Part 2 Merck 2011 -
`Annual Report
`Merck 2012 - Annual
`Report
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`Exhibit
`
`2143
`
`2144
`
`2145
`
`2145
`
`2146
`
`2146
`
`2147
`
`Questions regarding this receipt should be directed to the Patent Trial and Appeal Board at 571-272-7822.
`This e-mail is computer-generated. Do not reply because this e-mail address is not monitored.
`
`7